Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of N-Methyl-D-Aspartic Acid (Nmda). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.36 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL18528187 | 0.91 | CA2 (0.45) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL19741548 | 0.91 | CA2 (0.45) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL2220 | 0.91 | CA2 (0.45) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL163692 | 0.91 | CA2 (0.45) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL167682 | 0.91 | CA2 (0.45) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL27949540 | 0.89 | CA2 (0.44) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL11297426 | 0.89 | CA2 (0.44) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL10763594 | 0.89 | CA2 (0.44) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL6954583 | 0.89 | CA2 (0.44) | CA2CA4GNPATTDP1MME | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL28052876 | 0.86 | CA2 (0.42) | CA2CA4GNPATTDP1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022099-A1 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| CN-102256975-A | New polymorphic forms of azabicyclo-trifluoromethylbenzamide derivatives | SANOFI AVENTIS | 2011-11-23 | — | — | CN | disclosed |
| EP-2373651-A1 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065701-A1 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| EP-1532258-A4 | TREATMENT OF VASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE | SOCRATECH L L C (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050170359-A1 | Treatment of vascular dysfunction and alzheimer's disease | SOCRATECH L.L.C. | 2005-08-04 | — | — | US | disclosed |
| EP-1532258-A1 | TREATMENT OF VASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE | Socratech L.L.C. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003104466-A1 | TREATMENT OF VASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE | SOCRATECH, L.L.C. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022099-A1 | NOVEL POLYMORPHIC FORMS OF AN AZABICYCLO-TRIFLUOROMETHYL BENZAMIDE DERIVATIVE | ATP6V1B2, BRCA1, HLA-DRB1 | GLRA1 2265/4885SLC6A9 3434/4885OR51E2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.